替格瑞洛联合阿司匹林在中度缺血性卒中患者中的疗效与安全性:THALES随机临床试验探索性分析
本分析基于THALES随机试验,纳入9983例卒中患者,比较基线NIHSS 4~5分的中度卒中(3312例)与NIHSS 0~3分的较轻卒中(6671例)。
要点
- 中度缺血性卒中(NIHSS 4~5分)使用替格瑞洛联合阿司匹林,30天卒中或死亡风险方向与较轻卒中一致。
- 该分析为探索性,中度卒中亚组获益未达统计学显著,临床决策需结合个体出血风险。
核心结论
- 在中度缺血性卒中患者中,替格瑞洛联合阿司匹林较单用阿司匹林的一致获益与较轻卒中患者相似,且未进一步增加颅内出血或其他严重出血事件风险。
研究设计与样本
- THALES试验为随机双盲安慰剂对照研究,在28个国家414家医院于2018年1月至2019年12月开展。
- 本探索性分析纳入9983例卒中患者,排除2例NIHSS>5分及1031例短暂性脑缺血发作患者,其中中度卒中3312例、较轻卒中6671例。
- 干预为症状发作24小时内替格瑞洛(首日180 mg负荷,第2~30天90 mg每日两次)或安慰剂,所有患者均接受阿司匹林(首日300~325 mg,第2~30天75~100 mg每日)。
主要发现
- 中度卒中组主要结局事件率:替格瑞洛组7.6%(129/1671),安慰剂组9.1%(150/1641),HR 0.84(95%CI 0.66-1.06)。
- 中度卒中组女性1293例(39.0%),平均(SD)年龄64.5(10.8)岁;较轻卒中组女性2518例(37.7%),平均(SD)年龄64.8(11.2)岁。
关键数值与推荐
- 中度卒中定义为基线NIHSS评分4~5分,较轻卒中定义为NIHSS评分0~3分。
- 主要结局为30天内卒中或死亡时间,主要安全结局为严重出血时间。
临床怎么用
- 对NIHSS 4~5分的中度缺血性卒中患者,可参考THALES整体结果评估替格瑞洛联合阿司匹林30天方案的获益与出血风险。
- 本分析为探索性亚组,中度卒中组HR的95%CI跨1,不能据此单独确立该亚组的疗效结论。
局限性
- 本分析为THALES试验的探索性亚组分析,非预设主要分析,中度卒中组结果未达统计学显著。
- 原文未报告该亚组的具体局限性说明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prior trials of dual antiplatelet therapy excluded patients with moderate ischemic stroke. These patients were included in the Acute Stroke or Transient Ischaemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death (THALES) trial, but results have not been reported separately, raising concerns about safety and efficacy in this subgroup. OBJECTIVE: To evaluate the efficacy and safety of ticagrelor plus aspirin in patients with moderate ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] score of 4 to 5). DESIGN, SETTING, AND PARTICIPANTS: The THALES trial was a randomized trial conducted at 414 hospitals in 28 countries in January 2018 and December 2019. This exploratory analysis compared patients with moderate stroke (baseline NIHSS score of 4 to 5) with patients with less severe stroke (NIHSS score of 0 to 3). A total of 9983 patients with stroke were included in the present analysis, after excluding 2 patients with NIHSS scores greater than 5 and 1031 patients with transient ischemic attack. Data were analyzed from March to April 2021. INTERVENTIONS: Ticagrelor (180-mg loading dose on day 1 followed by 90 mg twice daily on days 2 to 30) or placebo within 24 hours after symptom onset. All patients received aspirin, 300 to 325 mg, on day 1 followed by aspirin, 75 to 100 mg, daily on days 2 to 30. Patients were observed for 30 additional days. MAIN OUTCOMES AND MEASURES: The primary outcome was time to stroke or death within 30 days. The primary safety outcome was time to severe bleeding. RESULTS: In total, 3312 patients presented with moderate stroke and 6671 presented with less severe stroke. Of those in the moderate stroke group, 1293 (39.0%) were female, and the mean (SD) age was 64.5 (10.8) years; of those in the less severe stroke group, 2518 (37.7%) were female, and the mean (SD) age was 64.8 (11.2) years. The observed primary outcome event rate in patients with moderate stroke was 7.6% (129 of 1671) for those in the ticagrelor group and 9.1% (150 of 1641) for those in the placebo group (hazard ratio, 0.84; 95% CI, 0.66-1.06); the primary outcome event rate in patients with less severe stroke was 4.7% (158 of 3359) for those in the ticagrelor group and 5.7% (190 of 3312) for those in the placebo group (hazard ratio, 0.82; 95% CI, 0.66-1.01) (P for interaction = .88). Severe bleeding occurred in 8 patients (0.5%) in the ticagrelor group and in 4 patients (0.2%) in the placebo group in those with moderate stroke compared with 16 patients (0.5%) and 3 patients (0.1%), respectively, with less severe stroke (P for interaction = .26). CONCLUSIONS AND RELEVANCE: In this study, patients with a moderate ischemic stroke had consistent benefit from ticagrelor plus aspirin vs aspirin alone compared with patients with less severe ischemic stroke, with no further increase in the risk of intracranial bleeding or other severe bleeding events. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03354429.
引用
- Wang Y, Pan Y, Li H, et al. Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke: An Exploratory Analysis of the THALES Randomized Clinical Trial. JAMA Neurol. 2021. PMID: 34244703. doi:10.1001/jamaneurol.2021.2440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。